Figure S1


A
**
% of bone marrow tumor (IgG2B+) cells
3.0
2.5
2.0
1.5
1.0
0.5
0.0
No Cell
IL-15
IL-12/15/18
% of spleen tumor (IgG2B+) cells
B
IL-15
IL-15 + 5TGM1
7.84
17.9
IL-15 + i.c.
IL-15 + NKG2D
5.61
14.6
IL-12/15/18
IL-12/15/18 + 5TGM1
3.41
7.63
IL-12/15/18 + i.c.
IL-12/15/18 + NKG2D
4.22
6.74
NK1.1
CD107a
% of CD107a+ NK cells
5TGM1
Anti-NKG2D
C
% of max
NKG2D
MFI
IL-15
IL12/15/18
% specific lysis
IL15
IL-12/15/18
8/1
4/1
2/1
1/1
0.5/1
E/T
D
IL-15 + i.c.
IL-15 + anti-NKG2D
6.1
37.4
IL-12/15/18 + i.c.
IL-12/15/18 + anti-NKG2D
91.5
93.5
IFN-γ
% of IFNγ+ NK cells
Isotype Control
Anti-NKG2D